Karyopharm Therapeutics (KPTI) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Strategic vision and pipeline focus

• Advancing innovation and growth strategy centered on XPO1 inhibition, with leadership in this area.

• Pipeline expansion targets new standards of care in myelofibrosis and endometrial cancer, building on a profitable multiple myeloma franchise.

• Selinexor available in over 40 countries, with growing reimbursement and global presence.

• Cash runway extends into Q1 2026, supporting ongoing R&D and clinical programs.

• U.S. peak sales potential for Selinexor projected at over $2 billion.

Financial performance and guidance

• Q2 revenue guidance in the U.S. adjusted to $105–$120 million; total revenue $145–$160 million.

• Expense guidance lowered to $250–$265 million.

• Minimum cash covenant of $25 million under new debt and convert agreements.

Myelofibrosis clinical development

• Selinexor targets both JAK and non-JAK pathways, showing additive or synergistic effects with ruxolitinib.

• Phase I trial in JAK-naïve patients showed 79% SVR35 and 58% TSS50 at week 24.

• Durable responses observed, with 100% of responders maintaining benefit at data cutoff.

• Manageable safety profile, with most adverse events familiar to clinicians and low discontinuation rates.

• Phase III trial ongoing, top-line data expected in H2 2025.